丹麦公司ALK以1.45亿美元的价格获得了neffy®的全球版权, Danish firm ALK secures global rights to neffy®, an adrenaline nasal spray for allergies, for $145M.

丹麦制药公司ALK确保了对耐菲的专属全球权利,这是用于紧急过敏反应的第一种肾上腺素鼻涕喷剂,美国、澳大利亚、新西兰、日本和中国除外。 Danish pharmaceutical company ALK has secured exclusive global rights to neffy®, the first adrenaline nasal spray for emergency allergic reactions, excluding the USA, Australia, New Zealand, Japan, and China. 这笔1.45亿美元的交易支持了ALK的财务目标,使其收入多样化。 The $145 million deal supports ALK's financial goals and diversifies its revenue. 欧盟和美国批准的Neffy为厌食症提供了无针紧急治疗选择,加强了快速反应能力。 Neffy®, approved in the EU and US, offers a needle-free emergency treatment option for anaphylaxis, enhancing quick response capabilities.